

# Closing remarks

Peter Halling, President & CEO



# Allergy<sup>+</sup> in essence

- Committed to creating value for shareholders, people and patients
- Strengthen AIT leadership with evidence-based portfolio and full coverage
- Diversify into food allergy and anaphylaxis, pursue adjacent allergic diseases
- Sustain high revenue growth, increase earnings and cash generation
- Prioritise high-potential growth levers
  - Focus commercial footprint in Europe
  - Strengthen R&D to target areas with high unmet medical need
  - Partnerships, licensing, business development
- Optimise to create the right foundation for scaling
  - Reduce complexity and optimise cost base
  - Invest in infrastructure, incl. digital solutions and AI
- Cultivate capabilities and conduct business sustainably
- Aspire to help 5 million people



ALK's Capital Markets Day 2024

# Thank you

